News & Events
August 25, 2023
C-Path’s Romero Appears on The BioCentury ShowKlaus Romero, Chief Science Officer at Critical Path Institute, occupies a rare role in the industry, as the top scientist in an organization whose mission is to solve industry-wide bottlenecks in drug development, with a path that leads directly to endorsement by FDA and other regulatory bodies. On the latest episode of The BioCentury Show, Romero......
May 25, 2023
C-Path Welcomes Red Nucleus ClinicalC-Path is proud to welcome Red Nucleus Clinical as the newest member of its Electronic Clinical Outcome Assessment (eCOA) Consortium. Comprised of 22 firms that provide electronic data collection technologies and services for capturing patient-reported outcome and other clinical outcome assessment data in clinical trials, eCOA Consortium members collaborate in a pre-competitive environment to support and conduct......
May 2, 2023
C-Path’s CDRC Meeting Highlights the Importance of Drug RepurposingThe Critical Path Institute’s CURE Drug Repurposing Collaboratory and FDA hosted their annual meeting April 18-20 to bring together stakeholders in drug repurposing. TUCSON, Ariz., May 4, 2023 — The CURE Drug Repurposing Collaboratory (CDRC) held a three-day annual meeting, April 18- 20, in Crystal City, VA. The event, hosted for both live and virtual......
February 17, 2023
C-Path Stands with Bruce Willis, Neurodegenerative Disease Community After FTD DiagnosisC-Path and its members stand with Bruce Willis and his family as they bravely revealed the difficult news of his Frontotemporal Degeneration (FTD) diagnosis yesterday. Also known as frontotemporal degeneration, the Association for Frontotemporal Degeneration (AFTD) defines FTD as a group of brain disorders caused by degeneration of the frontal and/or temporal lobes of the......
February 14, 2023
Regulus Therapeutics Joins PKDOCC-Path is excited to announce that Regulus Therapeutics, Inc. has joined the Polycystic Kidney Disease Outcomes Consortium (PKDOC) as a voting member. Regulus Therapeutics is a biotech company working to deliver life changing medicines to patients with orphan kidney diseases. The programs in their pipeline target kidney diseases of high unmet need, including ADPKD. PKDOC brings together diverse stakeholders from......